4//SEC Filing
Vivaldi Coelho Rogerio 4
Accession 0001415889-23-011446
CIK 0001821323other
Filed
Jul 23, 8:00 PM ET
Accepted
Jul 24, 7:44 PM ET
Size
7.8 KB
Accession
0001415889-23-011446
Insider Transaction Report
Form 4
Vivaldi Coelho Rogerio
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Common Stock
2023-07-21$19.24/sh+5,528$106,359→ 11,963 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-07-21−5,528→ 12,163 totalExercise: $19.24Exp: 2032-02-17→ Common Stock (5,528 underlying)
Footnotes (3)
- [F1]Includes 786 shares acquired by the Reporting Person pursuant to the Issuer's 2020 Employee Stock Purchase Plan ("ESPP") for the purchase periods from October 1, 2021 to March 31, 2023. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock . These transaction are exempt under Rule 16b-3(c).
- [F2]Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split.
- [F3]The option vested as to 25% of the underlying shares of common stock on February 18, 2023, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested.
Documents
Issuer
Sigilon Therapeutics, Inc.
CIK 0001821323
Entity typeother
Related Parties
1- filerCIK 0001610381
Filing Metadata
- Form type
- 4
- Filed
- Jul 23, 8:00 PM ET
- Accepted
- Jul 24, 7:44 PM ET
- Size
- 7.8 KB